212 related articles for article (PubMed ID: 37353788)
1. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
[TBL] [Abstract][Full Text] [Related]
2. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Theander E; Smolen JS
Ann Rheum Dis; 2022 Jun; 81(6):823-830. PubMed ID: 35210262
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Ann Rheum Dis; 2023 Apr; 82(4):496-506. PubMed ID: 36600178
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
[TBL] [Abstract][Full Text] [Related]
5. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Van Kuijk AWR; Nurmohamed MT; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Sharaf M; Noël W; Theander E; Smolen JS; Gossec L; van der Horst-Bruinsma IE
Rheumatology (Oxford); 2023 Oct; 62(10):3382-3390. PubMed ID: 36810788
[TBL] [Abstract][Full Text] [Related]
6. Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Gremese E; Ciccia F; Selmi C; Cuomo G; Foti R; Matucci-Cerinic M; Conti F; Fusaro E; Guggino G; Iannone F; Delle Sedie A; Perricone R; Idolazzi L; Moscato P; Theander E; Noël W; Bergmans P; Marelli S; Gossec L; Smolen JS;
Clin Exp Rheumatol; 2023 Mar; 41(3):735-743. PubMed ID: 36226614
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
Karadag O; Dalkilic E; Ayan G; Kucuksahin O; Kasifoglu T; Yilmaz N; Koca SS; Yazisiz V; Erten PT; Sayarlioglu M; Terzioglu ME; Erten S; Kalyoncu U
Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
[TBL] [Abstract][Full Text] [Related]
10. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
[TBL] [Abstract][Full Text] [Related]
11. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study.
Conaghan PG; Alten R; Deodhar A; Sullivan E; Blackburn S; Tian H; Gandhi K; Jugl SM; Strand V
RMD Open; 2020 Jun; 6(2):. PubMed ID: 32611650
[TBL] [Abstract][Full Text] [Related]
12. Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.
Gossec L; Theander E; Chakravarty SD; Bergmans P; Lavie F; Noël W; Sharaf M; Siebert S; Smolen JS
Arthritis Res Ther; 2023 Jun; 25(1):100. PubMed ID: 37296456
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
[TBL] [Abstract][Full Text] [Related]
14. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
15. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
[TBL] [Abstract][Full Text] [Related]
16. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
Queiro R; Brandy A; Rosado MC; Lorenzo A; Coto P; Carriles C; Alperi M; Ballina J
J Clin Rheumatol; 2018 Oct; 24(7):381-384. PubMed ID: 29509560
[TBL] [Abstract][Full Text] [Related]
17. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
19. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
Gossec L; Humphries B; Rutherford M; Taieb V; Willems D; Tillett W
Arthritis Res Ther; 2024 Feb; 26(1):50. PubMed ID: 38360699
[TBL] [Abstract][Full Text] [Related]
20. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
